At this time, New York Oncology Hematology does not have access to acquire and administer the new COVID prophylaxis shot Evusheld for immunocompromised patients. We await further guidance from NYS and will keep our patients updated.

Clinical Trials & Research

Ph2 Selinexor + Pembro Newly Dx Melanoma

A PHASE 2 OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SELINEXOR IN COMBINATION WITH PEMBROLIZUMAB IN RECURRENT ADVANCED MELANOMA (XPORT-MEL-033)

Disease Types: Melanoma,&nbs

Available at: {clinical_trial_location backspace="7"}Ph2 Selinexor + Pembro Newly Dx Melanoma, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}